Thursday, June 1, 2006

Proteolix Nets $45M

Proteolix, a San Francisco based biotech company, has raised $45M in a second round of funding. This brings their total amount received to $63M. Delphi Ventures led the round along with previous investors U.S. Venture Partners, Advanced Technology Partners, Latterell Venture Partners and The Vertical Group. Proteolix focuses on the treatment of cancer, inflammatory disease and autoimmunity. More information »